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Bacterial distribution and antimicrobial drug resistance 
were monitored in patients with bacterial bloodstream 
infections in rural hospitals in Ghana. In 2001–2002 and 
in 2009, Salmonella enterica serovar Typhi was the most 
prevalent pathogen. Although most S. enterica serovar 
Typhi isolates were chloramphenicol resistant, all isolates 
tested were susceptible to ciproﬂ  oxacin.
I
n Africa, fever is usually a synonym for malaria. 
However, evidence exists that a large proportion of fever 
of unknown origin (FUO) can be attributed to bacterial 
bloodstream infections (BBSI). Although Staphylococcus 
aureus is the predominant cause of BBSI in industrialized 
countries (1), in African countries such as Ghana or Kenya, 
gram-negative bacteria are identiﬁ  ed most often in BBSI 
(2,3). Furthermore, because of a lack of epidemiologic 
data, FUO in Africa is often treated sequentially, ﬁ  rst with 
antimalarial drugs and then, until some years ago, with 
antimicrobial drugs such as chloramphenicol. This strategy 
has often been ineffective (4).
The Study
In 2000 in hospitals in Ghana, we began to establish 
bacteriologic laboratories, which since then have 
participated in a biannual quality control program. For 
this quality control, 3 encoded bacterial species and their 
resistance to various antimicrobial drugs must be correctly 
identiﬁ  ed. Three of these hospitals took part in comparative 
epidemiologic studies of FUO during October 2001–April 
2002 and again during August–September 2009 with the 
objective of establishing a rational treatment approach 
(Figure). The hospitals were located in Eikwe, a coastal 
village that has a rural population of ≈2,000 residents; 
Assin Foso, which is on a regional trafﬁ  c route and has a 
rural/urban population of ≈15,000 residents; and Nkawkaw, 
which is on the national trafﬁ  c route that connects Accra 
with Kumasi and has an urban population of >45,000 
residents.
This study was approved by the ethical committee of 
the University Medical Center, Göttingen, Germany, and 
the participating hospitals in Ghana. The study design, 
patient selection, and diagnostic approaches were identical 
in both study periods; FUO was deﬁ  ned as fever >38.5°C 
of >1 week’s duration without a clear clinical or organ-
speciﬁ   c diagnosis. During the ﬁ   rst study period, 409 
patients with a wide range of ages (interquartile range 26 
years) were investigated. The second study period included 
258 patients with a similar age distribution (interquartile 
range 27 years).
Blood ﬁ  lm microscopy was used for malaria diagnosis. 
Bacteremia was determined by blood cultures; 2 mL or 5 
mL of blood was incubated in 20 mL or 50 mL of locally 
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Figure. Location of populations in a study of bacteremia and 
antimicrobial drug resistance over time, Ghana.made brain–heart infusion broth for <7 days at 37°C. Gram 
stains and subcultures on chocolate agar were performed 
after 24 h, 72 h, or when the media became turbid. Bacterial 
differentiation, according to good laboratory practice, and 
susceptibility testing by disk diffusion following National 
Committee for Clinical Laboratory Standards criteria 
(5) was done in Africa, and susceptibility testing that 
included quinolone susceptibility was conﬁ  rmed by broth 
microdilution at the University Medical Center, Göttingen. 
Respective tests for species differentiation were also 
repeated in Göttingen. The Vi phage typing scheme from 
the Colindale Institute London was used for Salmonella 
spp. typing (6).
Of the 212 bacterial isolates recovered from the blood 
cultures in the ﬁ  rst study period, 145 (68.4%) indicated a 
putative agent of septicemia (Table 1). Salmonella enterica 
was identiﬁ  ed in 100 (69.0%) of all pathogen-positive blood 
cultures, with S. enterica serovar Typhi accounting for 59 
(40.7%). Although the 2001 National Guidelines of Ghana 
listed chloramphenicol as ﬁ  rst choice for treating typhoid 
fever, >80% of all bacteria identiﬁ   ed (88.3% of all S. 
enteric serovar Typhi) were resistant to this drug. However, 
ciproﬂ   oxacin proved effective against most bacteria, 
especially against S. enterica serovar Typhi (Table 2). Thus, 
in 2004, the national guidelines replaced chloramphenicol 
with ciproﬂ  oxacin for treating typhoid fever (7).
To analyze the inﬂ  uence of ciproﬂ  oxacin on pathogen 
distribution and antimicrobial drug resistance in BBSI, in 
2009 we initiated a follow-up study. During the second 
study period, pathogenic bacteria were identiﬁ   ed in 48 
(48.5%) of 99 blood cultures; the rate of Plasmodium-
positive patients was signiﬁ  cantly higher (42.4% vs. 24.0%, 
p<0.0001; Table 1). S. enterica was found in 50% (24/48) 
of all pathogen-positive blood cultures with S. enterica 
serovar Typhi remaining the most prevalent species (Table 
1). Sampling was done during different months in the 
2 study periods; however, these covered mainly the dry 
seasons. Although seasonal differences might have had 
an effect on the pathogen distribution, our ﬁ  nding is in 
accordance with results from other tropical countries (8,9). 
In addition, although our study regions were 75–150 miles 
away from each other, and the hospitals were localized 
in villages or cities which differ notably with regards to 
population and structure, most S. enterica serovar Typhi 
isolates belonged to phage type D1. Therefore, the spread 
of a clonal bacterial population within Ghana cannot be 
discounted.
Although an extraordinarily high percentage of 
chloramphenicol resistance was obvious, this drug still 
was considered the ﬁ  rst choice treatment for typhoid fever 
in 2001 in Ghana. Therefore, the high rate of S. enterica 
serovar Typhi was not unexpected. Similarly, 91.7% of 
all S. enterica were resistant to chloramphenicol in 2009 
(Table 2). In both study periods, second-line antimicrobial 
agents, e.g., trimethoprim/sulfamethoxazole or ampicillin, 
also showed a high rate of resistance. This ﬁ  nding was in 
agreement with those of other studies from nonindustrialized 
countries (10). The rate of cefuroxime-resistant bacteria 
increased from 18.9% to 41.7% because of a higher 
percentage of cefuroxime-resistant enterobacteriaceae 
other than Salmonella (50.0% vs. 87.5%, Table 2).
In 2001–2002, most bacteria were susceptible to 
ciproﬂ  oxacin (Table 2), as had been shown for S. enterica 
from blood cultures of Nigerian patients (11). In contrast, 
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Table 1. Comparative monitoring of bloodstream infections, Ghana, 2001–2002 and 2009* 
Variable
July 2001–April 2002  July–September 2009 
Total  
Positive for 
Plasmodium spp.  Total
Positive for 
Plasmodium spp.
No. patients with fever of unknown origin  409 NA 258 NA
No. Plasmodium spp. positive/total no. tested (%)†  85/354 (24.0)  NA 75/177 (42.4)  NA
Total no. bacterial isolates  212 51 (24.1)  99 14 (14.1) 
Skin flora contaminants  67 24 (35.8)  51 10 (19.6) 
Potential pathogens  145 (100.0)  27 (18.6)  48 (100.0)  4 (8.3) 
Salmonella enterica serovars 100 (69.0)  20 (20.0)  24 (50.0)  4 (16.7) 
  Typhi  59 (40.7)  11 (18.6)  15 (31.3)  2 (13.3) 
 Paratyphi  1  (0.7)  NF  0 NF 
  Nontyphoid‡  40 (27.6)  9 (22.5)  9 (18.8)  2 (22.2) 
Staphylococcus aureus  16 (11.0)  3 (18.8)  3 (6.3)  NF 
Enterobacteriaceae other than Salmonella spp.  10 (6.9)  1 (10.0)  8 (16.7)  NF 
Pseudomonas spp.  7 (4.8)  2 (28.6)  5 (10.4)  NF 
Other§  12 (8.3)  1 (8.3)  8 (16.7)  NF 
*Values are no. (%) except as indicated. The total number of potential pathogens for each study period was set as 100%. Coagulase-negative 
staphylococci, microcooci, and bacilli were judged as skin flora contaminants. The ratio of Plasmodium spp.–positive patients in regard to bacterial 
species respective groups is indicated. NA, not applicable; NF, Plasmodium spp. not found. 
†Blood film for Plasmodium spp. was done in most cases. If the clinical situation, patient history, or blood count strongly indicated bacterial infection,
blood culture was taken as first diagnostic approach. 
‡S. enterica serovar Enteritidis and serovar Typhimurium. 
§Including Streptococcus spp., Enterococcus spp., Acinetobacter spp. Bacteremia and Drug Resistance, Ghana
for  S.  enterica serovar Typhi isolated in 1997–1999 in 
Kenya, MICs of ciproﬂ  oxacin were noticeably higher than 
for those strains isolated during 1988–1993 (12,13).
Although ciproﬂ   oxacin proved to be effective 
against  S. enterica in our study, the resistance rate of 
enterobacteriaceae other than S. enterica against this 
quinolone increased from zero in 2001–2001 to 50.0% in 
2009 (Table 2). Methicillin-resistant S. aureus was not 
identiﬁ  ed as a cause of BBSI during either period.
When we assessed the situation in individual regions, 
notable differences were obvious. Comprising 47.5% of all 
BBSI, typhoid fever was most prevalent in Assin Foso in 
2001–2002. In contrast, not even 1 case occurred in 2009. 
Analyzing the situation in that urban area, the following 
conditions were found: 1) sanitation was improved; 2) 
additional toilets were established; 3) ciproﬂ  oxacin was 
widely used in hospital for treating infections; and 4) 
ciproﬂ  oxacin was easily available at local street traders. 
Although the broad application of ciproﬂ  oxacin has to be 
critically discussed, the observed absence of typhoid fever 
in Assin Foso is impressive.
In contrast, S.  enterica serovar Typhi was isolated 
from 27.8% of cases of BBSI in Eikwe in 2001–2002 and 
remained at a high rate of 30.2% in 2009. In this small ﬁ  shing 
village, the situation differed noticeably from that in Assin 
Foso. Although additional toilets had been constructed, 
sanitation was not much improved; most residents still used 
the beach for defecation. In addition, ciproﬂ  oxacin was not 
extensively prescribed in the hospital and was not available 
at local street traders. Thus, educational programs to 
encourage use of public toilets plus adequate prescription of 
ciproﬂ  oxacin might help control typhoid here in the future.
Conclusions
Although Ghana implemented several measures 
to control typhoid, our study found that, depending on 
the region, S. enterica serovar Typhi remains the most 
prevalent bacterial species causing BBSI. This ﬁ  nding is 
in agreement with a recent study from the Ashanti region, 
where 12.4% of BBSI were caused by S. enterica serovar 
Typhi (14). In addition, emergent ciproﬂ  oxacin resistance 
has been described in Accra, the capital of Ghana (15). 
Therefore, the implementation of bacteriologic diagnosis 
should be considered even in smaller hospitals in a rural 
African setting to monitor pathogen distribution and 
resistance rates.
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Table 2. Ratio in percentages of antimicrobial drug–resistant bacterial isolates obtained from patients with bacterial bloodstream
infections, Ghana, 2001–2002 and 2009* 
Bacteria type and years  PEN OXA  AMP CEF GEN  SMX CMP CIP
Salmonella enterica serovar Typhi 
 2001–2002  93.3 1.7 0 86.7 88.3 0
 2009  100 0 0 100 100 0
Nontyphoid Salmonella spp. 
 2001–2002  100 20.0 12.5 90.0 82.5 0
 2009  100 0 0 88.9 77.8 0
Enterobacteriaceae other than Salmonella spp.
 2001–2002  100 50.0 60.0 80.0 80.0 0
 2009  100 87.5 37.5 62.5 50.0 50.0
Nonfermenters 
 2001–2002  91.7 75.0 16.7 41.7 100 0
 2009  100 100 15.4 53.8 92.3 0
Staphylococcus aureus 
 2001–2002  81.3 0 81.3 0 0 68.8
 2009  100 0 100 0 0
All bacteria 
 2001–2002  93.6 18.9 10.7 72.1 84.3 0
 2009  100 41.7 10.4 72.9 84.4 8.9
*Blank cells indicate no testing performed. PEN, penicillin; OXA, oxacillin; AMP, ampicillin; CEF, cefuroxime; GEN, gentamicin; SMX, 
trimethoprim/sulfamethoxazole; CMP, chloramphenicol; CIP, ciprofloxacin.  References
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